Compare · BBOT vs NVO
BBOT vs NVO
Side-by-side comparison of BridgeBio Oncology Therapeutics Inc. (BBOT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBOT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 734.3x BBOT ($236.5M).
- BBOT has been more active in the news (5 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 9 for BBOT).
- Company
- BridgeBio Oncology Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $236.5M
- $173.66B
- 1M return
- -42.35%
- -
- 1Y return
- -74.66%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 4
- Recent ratings
- 9
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BBOT
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by BridgeBio Oncology Therapeutics Inc.
- SEC Form 4 filed by BridgeBio Oncology Therapeutics Inc.
- SEC Form 4 filed by BridgeBio Oncology Therapeutics Inc.
- SEC Form 4 filed by BridgeBio Oncology Therapeutics Inc.
- Principal Accounting Officer Cobo Marc was granted 9,038 shares and covered exercise/tax liability with 203 shares, increasing direct ownership by 167% to 14,141 units (SEC Form 4) to satisfy withholding tax
- SEC Form EFFECT filed by BridgeBio Oncology Therapeutics Inc.
- SEC Form EFFECT filed by BridgeBio Oncology Therapeutics Inc.
- SEC Form 8-K filed by BridgeBio Oncology Therapeutics Inc.
- BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank